Cyclophosphamide-induced hyponatremia leading to status epilepticus in a breast cancer patient

BJMO - volume 17, issue 1, january 2023

E. Cassiers MD, N. Blockx MD, W. Teurfs MD


Cyclophosphamide (CP) is a well-known and extensively used immunosuppressive and antineoplastic agent. CP-induced hyponatremia remains an underestimated adverse event, although it can lead to severe complications and death. This case report describes the occurrence of life-threatening status epilepticus in a 74-year-old breast cancer patient due to CP-induced hyponatremia. The primary underlying mechanism seems to be impaired free water clearance, which is not influenced by ADH, but rather a direct effect of CP alkylating metabolites on the distal renal tubule. Future research is needed to further clarify the underlying pathophysiology and possible predisposing factors. Thorough monitoring of the patient’s hydration status and electrolytes until 48 hours after the first administration of CP seems strongly advisable.

(BELG J MED ONCOL 2023;17(1):27–30)

Read more

Doublets in the first-line treatment of metastatic renal cell cancer with clear cell histology

BJMO - volume 16, issue 2, march 2022

D. Schrijvers MD, PhD, S. Van Wambeke MD, W. Teurfs MD


The treatment of mRCC has undergone a tremendous evolution in the last decades. There are data that the doublets of checkpoints inhibitors with each other or with anti-angiogenic agents improve PFS compared to sunitinib alone.

In this article, we review the different combinations and give some guidance for their use.

(BELG J MED ONCOL 2022;16(2):48–52)

Read more

BRCA1 and BRCA2 mutations in prostate cancer: consequences and implications

BJMO - volume 15, issue 6, october 2021

D. Schrijvers MD, PhD, W. Teurfs MD, S. Van Wambeke MD


BRCA mutations play an important role in prostate cancer. All patients with high-risk localised or metastatic prostate cancer should be tested for somatic mutations and, if present, for germline mutations. BRCA muta-tions translate in a more aggressive prostate cancer with a worse prognosis. If these mutations are present, PARP inhibitors may be part of the treatment strategy.

(BELG J MED ONCOL 2021;15(6):283-5)

Read more

The role of docetaxel in prostate cancer

BJMO - volume 9, issue 5, september 2015

D. Schrijvers MD, PhD, W. Teurfs MD

Docetaxel has shown to improve survival and quality of life in patients with castration-resistant prostate cancer. Its place as first-line treatment in this population is challenged by new hormonal treatments, but it still has a place in this setting. Its role in metastatic hormone-sensitive prostate cancer is becoming clearer and docetaxel may be offered to selected patients. In localised high-risk prostate cancer the place of docetaxel remains to be determined.

(BELG J MED ONCOL 2015;9(5):191–93)

Read more